SEC Filing | Kiniksa Pharmaceuticals

Name of Reporting Person

  Ameriprise Financial, Inc.

  S.S. or I.R.S. Identification No. of Above Person

  IRS No. 13-3180631

Check the Appropriate Box if a Member of a Group

(a) ☐ (b) ☒*

* This filing describes the reporting person’s relationship with other persons, but the reporting person does not affirm the existence of a group.

SEC Use Only

Citizenship or Place of Organization

Delaware

View:

Download DOC

Download PDF

Download XLS

SC 13G/A

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13G

Amendment #1

Under the Securities and Exchange Act of 1934

Kiniksa Pharmaceuticals, Ltd

(Name of Issuer)

Class A Common Stock

(Title of Class of Securities)

G5269C101

(CUSIP Number)

December 31, 2020

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

This Schedule is filed pursuant to Rule 13d-1(b)

The information required in the remainder of this cover page (except any items to which the form provides a cross-reference) shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act.

CUSIP NO. G5269C101

CUSIP NO. G5269C101

CUSIP NO. G5269C101

CUSIP NO. G5269C101


1(a)	Name of Issuer:	Kiniksa Pharmaceuticals, Ltd

1(b)	Address of Issuer’s Principal Executive Offices:	Clarendon House, 2 Church Street
		Hamilton HM11, Bermuda

2(a)	Name of Person Filing:	(a) Ameriprise Financial, Inc. (“AFI”)
		(b) Columbia Management Investment Advisers, LLC (“CMIA”)
		(c) Columbia Wanger Asset Management, LLC (“CWAM”)
		(d) Columbia Acorn Fund(“Fund”)

2(b)	Address of Principal Business Office:	(a) Ameriprise Financial, Inc.
		145 Ameriprise Financial Center
		Minneapolis, MN 55474
		(b) 225 Franklin St.
		Boston, MA 02110
		(c) 71 S Wacker Drive, Suite 2500
		Chicago, IL 60606
		(d) 71 S Wacker Drive, Suite 2500
		Chicago, IL 60606

2(c)	Citizenship:	(a) Delaware
		(b) Minnesota
		(c) Delaware
		(d) Massachusetts

2(d)	Title of Class of Securities:	Class A Common Stock

2(e)	Cusip Number:	G5269C101

3	Information if statement is filed pursuant to Rules 13d-1(b) or 13d-2(b):

	(a) Ameriprise Financial, Inc.

	A parent holding company in accordance with Rule 13d-1(b)(1)(ii)(G). (Note: See Item 7)

	(b) Columbia Management Investment Advisers, LLC

	An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E).

	(c) Columbia Wanger Asset Management, LLC

	An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E).

	(d) Columbia Acorn Fund

	An investment company registered under Section 8 of the Investment Company Act.


4		Incorporated by reference to Items (5)-(9) and (11) of the cover page pertaining to each reporting person.

		CMIA, CWAM and AFI do not directly own any shares of Common Stock of the issuer. As the investment adviser to the Fund and various other unregistered and registered investment companies and other managed accounts, CMIA and CWAM may be deemed to beneficially own the shares reported herein by the Fund. Accordingly, the shares reported herein by CMIA and CWAM include those shares separately reported herein by the Fund.

		AFI, as the parent company of CMIA and CWAM, may be deemed to beneficially own the shares reported herein by those reporting persons. Accordingly, the shares reported herein by AFI include those shares separately reported herein by those reporting persons.

		Each of AFI, CMIA and CWAM disclaims beneficial ownership of any shares reported on this Schedule.

5		Ownership of 5% or Less of a Class: Not Applicable

6		Ownership of more than 5% on Behalf of Another Person:

		To the knowledge of AFI, CMIA, CWAM and the Fund, no other persons besides AFI, CMIA, CWAM and the Fund and those persons for whose shares of common stock CMIA, CWAM and AFI report beneficial ownership have the right to receive or the power to direct the receipt of dividends from or the proceeds from the sale of the securities of the issuer reported herein. As of December 31, 2020, only the Fund owned more than 5% of the class of securities reported herein.

		Any remaining shares reported herein by CMIA and CWAM are held by various other funds or accounts managed by CMIA and CWAM which each have the right to receive any dividends paid by the issuer and could terminate their respective investment advisory relationship with CMIA and CWAM and then subsequently direct the use of proceeds from the sale of the common stock owned by such fund or account. To CMIA’s and CWAM’s knowledge, none of these other funds or accounts own more than 5% of the outstanding shares of the issuer as December 31, 2020.

7		Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company:

		AFI: See Exhibit I

8		Identification and Classification of Members of the Group:

		Not Applicable

9		Notice of Dissolution of Group:

		Not Applicable

Certification:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired in the ordinary course of business and were not acquired for the purpose of and do not have the effect of changing or influencing the control of the issuer of such securities and were not acquired in connection with or as a participant in any transaction having such purposes or effect.

Signature

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete, and correct.

Dated: February 12, 2021


Ameriprise Financial, Inc.

By:		/s/ Paul Goucher
Name:		Paul Goucher
Title:		Senior Vice President and Assistant General Counsel

Columbia Management Investment Advisers, LLC

By:		/s/ Paul Goucher
Name:		Paul Goucher
Title:		Senior Vice President and Assistant Secretary

Columbia Wanger Asset Management, LLC

By:		/s/ Joseph C. LaPalm
Name:		Joseph C. LaPalm
Title:		Chief Compliance Officer

Columbia Acorn Fund

By:		/s/ Joseph C. LaPalm
Name:		Joseph C. LaPalm
Title:		Vice President

Contact Information

Mark D. Braley

Vice President

Head of Reporting and Data Management |

Global Operations and Investor Services

Telephone: (617) 747-0663

Exhibit Index


Exhibit I		Identification and Classification of the Subsidiary which acquired the Security Being Reported on by the Parent Holding Company.

Exhibit II		Joint Filing Agreement

EX-99.I

Exhibit I

Schedule 13G

Ameriprise Financial, Inc., a Delaware Corporation, is a parent holding company. The classification and identity of the relevant subsidiaries is as follows:

Investment Adviser – Columbia Management Investment Advisers, LLC is an investment adviser registered under section 203 of the Investment Advisers Act of 1940.

Investment Adviser – Columbia Wanger Asset Management, LLC is an investment adviser registered under section 203 of the Investment Advisers Act of 1940.

EX-99.II

Exhibit II

Schedule 13G

Joint Filing Agreement

The undersigned persons agree and consent to the joint filing on their behalf of this Schedule 13G dated February 12, 2021 in connection with their beneficial ownership of Kiniksa Pharmaceuticals, Ltd. Each of Columbia Acorn Fund, Columbia Wanger Asset Management, LLC and Columbia Management Investment Advisers, LLC authorizes Ameriprise Financial, Inc. to execute the Schedule 13G to which this Exhibit is attached and make any necessary amendments thereto.


Ameriprise Financial, Inc.

By:		/s/ Paul Goucher
Name:		Paul Goucher
Title:		Senior Vice President and Assistant General Counsel

Columbia Management Investment Advisers, LLC

By:		/s/ Paul Goucher
Name:		Paul Goucher
Title:		Senior Vice President and Assistant Secretary

Columbia Wanger Asset Management, LLC

By:		/s/ Joseph C. LaPalm
Name:		Joseph C. LaPalm
Title:		Chief Compliance Officer

Columbia Acorn Fund

By:		/s/ Joseph C. LaPalm
Name:		Joseph C. LaPalm
Title:		Vice President